The Chinese drug administration denied the application of Shanghai Shyndec Pharmaceutical's (SHA:600420) unit, Sinopharm Zhijun (Shenzhen) Pharmaceutical, to market fosfomycin tromethamine granules, according to a Shanghai Stock Exchange disclosure on Friday.
The application did not meet relevant requirements for drug registration, the pharmaceutical company said.
The drug was developed to treat infections caused by sensitive Escherichia coli, Enterococcus faecalis, Klebsiella pneumoniae, Citrobacter, Enterobacter, and Proteus mirabilis, such as acute simple urinary tract infection.
The company, which spent 11.5 million yuan into the drug's research and development, said it will re-initiate the research, application and registration work for the drug.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.